retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple Agonism Based Therapies for

& Meier, J

The result is a drug that reduces how much you eat, improves how your body processes sugar, and increases how many calories your body burns, all at once

79 While the mechanisms likely involve both weight-dependent and independent effects, dedicated BP-focused trials in OSA populations are necessary to clarify the causal pathways and magnitude of effect

They were all large-scale trials involving 3,000 to 18,000 patients who were either at high risk of or having established ASCVD, with trial durations ranging from 15 to 60 months

The gastrointestinal (GI) tract is commonly affected in both type 1 and type 2 diabetes, leading to increased morbidity and healthcare costs, and often presents a diagnostic and therapeutic challenge

It slows gastric emptying (leading to early satiety), increases insulin secretion, and signals the brain to reduce appetite